Agency Forms Undergoing Paperwork Reduction Act Review, 62791-62793 [2023-19708]
Download as PDF
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices
PBMs preferential placements or
exclusionary access for its nonblockbuster drugs, thereby excluding
rivals. This sort of cross-product
bundling scheme can lock out new
competitors—even if their products are
more affordable or effective. Based on
these facts, the Commission’s complaint
charged that Amgen’s acquisition of
Horizon would give Amgen the ability
and incentive to engage in similar crossproduct bundling that would exclude
Horizon’s rivals and maintain its
monopolies, harming patients in the
long run.
The order announced today prohibits
Amgen from engaging in any crossproduct bundling or exclusionary
rebating schemes involving Horizon’s
monopoly drugs. Several features of this
conduct suggest that an order alone can
effectively halt it. For example, because
this deal would not give a firm control
over products or services that its rivals
use to compete, it does not raise
traditional concerns about degrading
competitors’ access to key inputs or
improper information exchange, which
can be achieved through subtle and
varied means that are difficult to detect.
By contrast, Amgen can only engage in
exclusionary rebating schemes and
cross-product bundling in partnership
with PBMs, who would need to agree to
accept rebates in exchange for
privileging Amgen’s drugs or excluding
those of its rivals. Given the significant
financial sums involved, these
agreements would be documented, and
the FTC’s proposed order will require
Amgen to regularly submit all such
agreements and other key documents to
aid the Commission in identifying even
implicit efforts to bundle. Amgen is also
required to notify its trading partners
about the FTC’s order, ensuring that
market participants are on alert about
the prohibited conduct and are
positioned to report any suspected
violations.11
The proposed order also prohibits
Amgen from acquiring any drugs that
could compete with Horizon’s two
monopoly drugs without first seeking
the Commission’s approval. Because
Amgen could try to neutralize Horizon’s
rivals not just through excluding them
but also through acquiring them, this
prior approval provision will position
the FTC to block acquisitions that
would unlawfully maintain Horizon’s
monopolies.12
11 Any suspicions of order violations by Amgen
may be submitted to the Bureau of Competition by
email at antitrust@ftc.gov.
12 Statement of the Commission on Use of Prior
Approval Provisions in Merger Orders, Fed. Trade
Comm’n (Oct. 25, 2021), https://www.ftc.gov/
VerDate Sep<11>2014
17:37 Sep 12, 2023
Jkt 259001
Critically, the six state attorneys
general who joined the FTC’s complaint
will be able to independently monitor
Amgen’s compliance with the proposed
order. California, Illinois, Minnesota,
New York, Washington, and Wisconsin
will also have access to Amgen’s
documents and reports and will serve as
another key check on any violations. I
am grateful to our state partners for their
close collaboration on this enforcement
matter, and empowering them to
independently monitor compliance with
our consent orders—and take corrective
action as appropriate—positions our
remedies for greater success.
The FTC assesses each merger based
on the specific facts at hand, and there
is no guarantee that the relief achieved
in this matter would adequately resolve
concerns about cross-product bundling
in any future merger actions. A distinct
feature of the conduct at issue here is
that it involves bundling across different
insurance benefit arrangements, which
makes it easier to detect. The conduct
also involves orphan drugs for rare
diseases, the selection and
administration of which involves
providers with incentives to resist and
report exclusionary behavior. As the
Commission evaluates proposals to
settle charges in future pharmaceutical
mergers, we will continue to learn from
past experience and seek to fully protect
the public from deals that violate the
antitrust laws. The merger guidelines
we recently proposed with the U.S.
Department of Justice further describe
how we will assess transactions to
determine if they may lessen
competition or tend to create a
monopoly.13
Tackling unlawful pharmaceutical
mergers is just one aspect of the FTC’s
work addressing high drug prices. The
bundling and exclusionary rebating
practices at issue in this matter
highlight deeper concerns about how
pharmaceutical companies and
pharmacy benefit managers may work
together to deprive Americans of access
to affordable drugs. The FTC continues
to scrutinize these practices through its
inquiry into PBMs.14 And our teams
system/files/documents/public_statements/
1597894/p859900priorapprovalstatement.pdf.
13 U.S. Dep’t of Justice and Fed. Trade Comm’n,
Merger Guidelines: Draft for Public Comment
Purposes (July 19, 2023), https://www.ftc.gov/
system/files/ftc_gov/pdf/p859910draftmerger
guidelines2023.pdf; Statement of Chair Lina M.
Khan Joined by Commissioner Rebecca Kelly
Slaughter and Commissioner Alvaro M. Bedoya
Regarding FTC–DOJ Proposed Merger Guidelines
(July 19, 2023), https://www.ftc.gov/system/files/
ftc_gov/pdf/p234000_chair_statement_re_draft_
merger_guidelines.pdf.
14 Statement of Chair Lina M. Khan Regarding
6(b) Study of Pharmacy Benefit Managers,
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
62791
will continue to challenge unlawful
practices that raise drug prices, inhibit
access, stifle innovation, or otherwise
hurt patients.
[FR Doc. 2023–19809 Filed 9–12–23; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–23–1198]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Use of the
Cyclosporiasis National Hypothesis
Generating Questionnaire (CNHGQ)
During Investigations of Foodborne
Disease Clusters and Outbreaks’’ to the
Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on July 7, 2023, to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
Commission File No. P221200 (June 8, 2022),
https://www.ftc.gov/system/files/ftc_gov/pdf/
Statement-Khan-6b-Study-Pharmacy-BenefitManagers.pdf; Press Release, Fed. Trade Comm’n,
FTC Further Expands Inquiry Into Prescription
Drug Middlemen Industry Practices (June 8, 2023),
https://www.ftc.gov/news-events/news/pressreleases/2023/06/ftc-further-expands-inquiryprescription-drug-middlemen-industry-practices.
E:\FR\FM\13SEN1.SGM
13SEN1
62792
Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Use of the Cyclosporiasis National
Hypothesis Generating Questionnaire
(CNHGQ) During Investigations of
Foodborne Disease Clusters and
Outbreaks (OMB Control No. 0920–
1198, Exp. 9/30/2023)—Extension—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC) is requesting a threeyear Paperwork Reduction Act (PRA)
clearance for an Extension of the
information collection request (ICR)
‘‘Use of the Cyclosporiasis National
Hypothesis Generating Questionnaire
(CNHGQ) During Investigations of
Foodborne Disease Clusters and
Outbreaks’’ (OMB Control No. 0920–
1198, Exp. Date 09/30/2023).
An estimated one in six Americans
per year becomes ill with a foodborne
disease. Foodborne outbreaks of
cyclosporiasis, caused by the parasite
Cyclospora cayetanensis, have been
reported in the United States since the
mid-1990s and have been linked to
various types of fresh produce. During
the 15-year period from 2000–2014, 31
U.S. foodborne outbreaks of
cyclosporiasis were reported; the total
case count was 1,562. It is likely that
more cases (and outbreaks) occurred
than were reported. In addition, because
of insufficient data, many of the
reported cases could not be directly
linked to an outbreak or to a particular
food vehicle. In recent years, from 2018
onward the number of cases reported
annually to CDC has increased
substantially to over 1,000 cases;
notably, in 2018 and again in 2019 over
2,000 cases were reported.
Collecting the requisite data for the
initial hypothesis-generating phase of
investigations of multistate foodborne
disease outbreaks is associated with
multiple challenges, including the need
to have high-quality hypothesisgenerating questionnaire(s) that can be
used effectively in multijurisdictional
investigations. Such a questionnaire was
developed in the past for use in the
context of foodborne outbreaks caused
by bacterial pathogens; that
questionnaire is referred to as the
Standardized National Hypothesis
Generating Questionnaire (SNHGQ).
However, not all of the data elements in
the SNHGQ are relevant to the parasite
Cyclospora (e.g., questions about
consumption of meat and dairy
products); on the other hand, additional
data elements (besides those in the
SNHGQ) are needed to capture
information pertinent to Cyclospora and
to fresh produce vehicles of infection.
Therefore, the Cyclosporiasis National
Hypothesis Generating Questionnaire
(CNHGQ) has been developed, by using
core data elements from the SNHGQ and
incorporating modifications pertinent to
Cyclospora.
The core data elements from the
SNHGQ were developed by a series of
working groups comprised of local,
State, and Federal public health
partners. Subject matter experts at CDC
developed the CNHGQ by modifying the
SNHGQ to include and focus on data
elements pertinent to Cyclospora/
cyclosporiasis. Input also was solicited
from State public health partners.
Because relatively few data elements in
the SNHGQ needed to be modified, a
full vetting process was determined not
to be necessary. The CNHGQ has been
designed for administration over the
telephone by public health officials, to
collect data elements from case-patients
or their proxies. The data that are
collected will be pooled and analyzed at
CDC, to generate hypotheses about
potential vehicles/sources of infection.
CDC requests OMB approval to collect
information via the CNHGQ from
persons who have developed
symptomatic cases of Cyclospora
infection during periods in which
increased numbers of such cases are
reported (typically, during spring and
summer months). In part because
molecular typing methods are not yet
available for C. cayetanensis, it is
important to interview all case-patients
identified during periods of increased
reporting, to help determine if their
cases could be part of an outbreak(s).
The CNHGQ is not expected to entail
substantial burden for respondents. The
estimated total annualized burden
associated with administering the
CNHGQ is 1875 hours (approximately
2,500 individuals interviewed × 45
minutes/response). There will be no
costs to respondents other than their
time.
ddrumheller on DSK120RN23PROD with NOTICES1
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Form name
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Ill individuals identified with cyclosporiasis ....
Cyclosporiasis National Hypothesis Generating Questionnaire.
2,500
1
45/60
VerDate Sep<11>2014
17:37 Sep 12, 2023
Jkt 259001
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
E:\FR\FM\13SEN1.SGM
13SEN1
Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2023–19708 Filed 9–12–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–23–22GA]
ddrumheller on DSK120RN23PROD with NOTICES1
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Expanding
PrEP in Communities of Color (EPICC)’’
to the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on June 13, 2022, to obtain
comments from the public and affected
agencies. CDC received four comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
VerDate Sep<11>2014
17:37 Sep 12, 2023
Jkt 259001
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Expanding PrEP in Communities of
Color (EPICC)—New—National Center
for HIV, Viral Hepatitis, STD, TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The CDC is requesting approval for 36
months for a data collection titled,
Expanding PrEP in Communities of
Color (EPICC). The purpose of this study
is to implement and evaluate the
effectiveness of a clinic-based
intervention that utilizes evidencebased education and support tools to:
(1) increase provider knowledge of and
comfort with preexposure prophylaxis
(PrEP) modalities in clinical practice;
and (2) improve PrEP adherence among
young men who have sex with men
(YMSM). The information collected in
this study will be used to: (1) describe
real-world PrEP use including factors
influencing selection and change of
PrEP regimens; (2) understand and
describe barriers and facilitators
impacting the implementation of new
PrEP modalities in clinical practice; (3)
evaluate the feasibility and acceptability
of the EPICC+ mobile app among YMSM
on PrEP; and (4) evaluate the feasibility
and acceptability of implementing a
provider training.
This study has two aims: In Aim 1,
the study team will deliver training to
health providers that will focus on
implementation of evidence-based tools
to enhance the providers’ ability to
engage in PrEP screening, counseling,
initiation and to provide support for
adherence and persistence. The study
will utilize web-based computerassisted surveys to measure healthcare
provider knowledge both pre- and posttraining. Post-training and at three
months, providers will complete a
patient interaction assessment via
teleconference and receive personalized
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
62793
feedback to assess and enhance their
tailored motivational interviewing
skills.
For Aim 2a, the study will initiate an
effectiveness-implementation trial with
400 YMSM to test the effectiveness of
the EPICC+ intervention package in
increasing PrEP adherence and
persistence among YMSM. The
intervention will utilize a mobile appbased platform, EPICC+, to support
ongoing participant engagement and
monitoring, as well as to provide
additional adherence support. YMSM
participants will complete quarterly
web-based computerized assessments
during the 18-month follow up period.
The assessments will measure PrEP
knowledge, usage, and choice, and
gather information about sexual
behaviors, HIV status of partners, and
substance use. YMSM participants will
be mailed four dried blood spot
collection kits to measure PrEP
metabolites (baseline, six, 12, and 18
months). To further examine the
participant experience and intervention
satisfaction, a subset of YMSM
participants (45) will be invited to
participate in a web-based exit
interview at the close of the follow up
period (18 months). Additionally, study
staff will collect data to measure mobile
app use and conduct medical record
abstractions three times during the
follow up period (six, 12, and 18
months).
In Aim 2b, the study team will
conduct focus groups with health
providers from the participating clinics
to gather feedback on overall
perceptions about the effectiveness of
the intervention and the barriers and
facilitators to implementation of the
evidence-based tools (EBT) within their
clinical site. Providers will complete a
short web-based computer-assisted prefocus group survey prior to the virtual
two-hour focus group. To describe PrEP
services implementation at the facility
level, each participating clinic will
complete a web-based computerassisted clinic assessment at six-month
intervals during the three-year data
collection period (baseline, six, 12, 18,
24, 30, and 36 months).
This study will be carried out in nine
clinics located in Chicago, IL; Bronx,
New York City, NY; Philadelphia, PA;
Charlotte, NC; Raleigh, NC; Tuscaloosa,
AL; Tampa, FL; Orlando, FL; and
Houston, TX. Aim 1 will include
healthcare providers from the nine
clinic sites, all involved in the direct
delivery of PrEP services. Providers may
include but are not limited to medical
doctors, nurses, adherence counselors,
pharmacists, and social workers. Health
providers will be recruited via staff
E:\FR\FM\13SEN1.SGM
13SEN1
Agencies
[Federal Register Volume 88, Number 176 (Wednesday, September 13, 2023)]
[Notices]
[Pages 62791-62793]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-19708]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-23-1198]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Use of the Cyclosporiasis National
Hypothesis Generating Questionnaire (CNHGQ) During Investigations of
Foodborne Disease Clusters and Outbreaks'' to the Office of Management
and Budget (OMB) for review and approval. CDC previously published a
``Proposed Data Collection Submitted for Public Comment and
Recommendations'' notice on July 7, 2023, to obtain comments from the
public and affected agencies. CDC did not receive comments related to
the previous notice. This notice serves to allow an additional 30 days
for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who
[[Page 62792]]
are to respond, including, through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Use of the Cyclosporiasis National Hypothesis Generating
Questionnaire (CNHGQ) During Investigations of Foodborne Disease
Clusters and Outbreaks (OMB Control No. 0920-1198, Exp. 9/30/2023)--
Extension--National Center for Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC) is requesting
a three-year Paperwork Reduction Act (PRA) clearance for an Extension
of the information collection request (ICR) ``Use of the Cyclosporiasis
National Hypothesis Generating Questionnaire (CNHGQ) During
Investigations of Foodborne Disease Clusters and Outbreaks'' (OMB
Control No. 0920-1198, Exp. Date 09/30/2023).
An estimated one in six Americans per year becomes ill with a
foodborne disease. Foodborne outbreaks of cyclosporiasis, caused by the
parasite Cyclospora cayetanensis, have been reported in the United
States since the mid-1990s and have been linked to various types of
fresh produce. During the 15-year period from 2000-2014, 31 U.S.
foodborne outbreaks of cyclosporiasis were reported; the total case
count was 1,562. It is likely that more cases (and outbreaks) occurred
than were reported. In addition, because of insufficient data, many of
the reported cases could not be directly linked to an outbreak or to a
particular food vehicle. In recent years, from 2018 onward the number
of cases reported annually to CDC has increased substantially to over
1,000 cases; notably, in 2018 and again in 2019 over 2,000 cases were
reported.
Collecting the requisite data for the initial hypothesis-generating
phase of investigations of multistate foodborne disease outbreaks is
associated with multiple challenges, including the need to have high-
quality hypothesis-generating questionnaire(s) that can be used
effectively in multijurisdictional investigations. Such a questionnaire
was developed in the past for use in the context of foodborne outbreaks
caused by bacterial pathogens; that questionnaire is referred to as the
Standardized National Hypothesis Generating Questionnaire (SNHGQ).
However, not all of the data elements in the SNHGQ are relevant to the
parasite Cyclospora (e.g., questions about consumption of meat and
dairy products); on the other hand, additional data elements (besides
those in the SNHGQ) are needed to capture information pertinent to
Cyclospora and to fresh produce vehicles of infection. Therefore, the
Cyclosporiasis National Hypothesis Generating Questionnaire (CNHGQ) has
been developed, by using core data elements from the SNHGQ and
incorporating modifications pertinent to Cyclospora.
The core data elements from the SNHGQ were developed by a series of
working groups comprised of local, State, and Federal public health
partners. Subject matter experts at CDC developed the CNHGQ by
modifying the SNHGQ to include and focus on data elements pertinent to
Cyclospora/cyclosporiasis. Input also was solicited from State public
health partners. Because relatively few data elements in the SNHGQ
needed to be modified, a full vetting process was determined not to be
necessary. The CNHGQ has been designed for administration over the
telephone by public health officials, to collect data elements from
case-patients or their proxies. The data that are collected will be
pooled and analyzed at CDC, to generate hypotheses about potential
vehicles/sources of infection.
CDC requests OMB approval to collect information via the CNHGQ from
persons who have developed symptomatic cases of Cyclospora infection
during periods in which increased numbers of such cases are reported
(typically, during spring and summer months). In part because molecular
typing methods are not yet available for C. cayetanensis, it is
important to interview all case-patients identified during periods of
increased reporting, to help determine if their cases could be part of
an outbreak(s). The CNHGQ is not expected to entail substantial burden
for respondents. The estimated total annualized burden associated with
administering the CNHGQ is 1875 hours (approximately 2,500 individuals
interviewed x 45 minutes/response). There will be no costs to
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Ill individuals identified with Cyclosporiasis 2,500 1 45/60
cyclosporiasis. National Hypothesis
Generating
Questionnaire.
----------------------------------------------------------------------------------------------------------------
[[Page 62793]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2023-19708 Filed 9-12-23; 8:45 am]
BILLING CODE 4163-18-P